D2.1 - Glossary of terms and definitions used

Amy Rogers; Rachel Copland; Sonia Houston Pichardo; Kate Harwood; Christa Müller-Vössing; Petra Naster; Linda Rutgrink; Ute Kohlhaas; Evert-Ben van Veen; Jozef Aerts; Bianca Schnalzer; Christoph Reiter; Robert Rehb

D2.1 - Glossary of terms and definitions used

Amy Rogers (Lead / Corresponding author), Rachel Copland (Lead / Corresponding author), Sonia Houston Pichardo (Lead / Corresponding author), Kate Harwood (Contributing member), Christa Müller-Vössing (Contributing member), Petra Naster (Contributing member), Linda Rutgrink (Contributing member), Ute Kohlhaas (Contributing member), Evert-Ben van Veen (Contributing member), Jozef Aerts (Contributing member), Bianca Schnalzer (Contributing member), Christoph Reiter (Contributing member), Robert Rehb (Contributing member)

Research output: Other contribution

Abstract

This document reports the processes used to develop a glossary of terms and definitions used within WP2 (task 2.1.1). The consortium agreed to expand the WP2 glossary to a project-level glossary since a common language should be established not only within but also across work packages. The aim of the glossary is to establish a common language within the project and to aid understanding of key terms that will feature in project outputs. The glossary itself, presented in the document, may be updated during the Trials@Home project so that important new terms can be added, obsolete terms removed, or existing terms updated to significant new insights. This approach has been chosen to reflect the fast-changing decentralised clinical trial landscape. The current version of the glossary can also be found online.

Original language	English
Type	Project Deliverable - Glossary of Decentralised Clinical Trial terminology
Media of output	text
Publisher	Trials@Home
Number of pages	12
Publication status	Published - 28 Feb 2020

Access to Document

https://trialsathome.com/trialshome-glossary/

1 Active

Trials@Home: Center of Excellence – Remote Decentralised Clinical Trials (Joint with 30 other participants, University Medical Centre Utrecht as lead)
MacDonald, T. (Investigator) & Mackenzie, I. (Investigator)
COMMISSION OF THE EUROPEAN COMMUNITIES
1/09/19 → 30/11/25
Project: Research

1 Other report
1 Other contribution

D1.1 First set of recommendations for RDCTs (to be implemented in the pan-EU pilot DCT)
Rogers, A. (Lead / Corresponding author), Mackenzie, I. (Lead / Corresponding author) & Kimberley, H., 26 Aug 2020, Trials@Home. 46 p.
Research output: Book/Report › Other report

Open Access
D1.2 Criteria for selection of appropriate trials
De Paoli, G. (Lead / Corresponding author), Rogers, A. (Lead / Corresponding author), Mackenzie, I. (Lead / Corresponding author), MacDonald, T., Mitchell, L., Subbarayan, S., Copland, R., Strachan, D., Coyle, J. & Kimberley, H., 26 Aug 2020, 10 p. Trials@Home.
Research output: Other contribution

Open Access

Cite this

@misc{b19d381bab8848769f42d83e3f93ca26,

title = "D2.1 - Glossary of terms and definitions used",

abstract = "This document reports the processes used to develop a glossary of terms and definitions used within WP2 (task 2.1.1). The consortium agreed to expand the WP2 glossary to a project-level glossary since a common language should be established not only within but also across work packages. The aim of the glossary is to establish a common language within the project and to aid understanding of key terms that will feature in project outputs. The glossary itself, presented in the document, may be updated during the Trials@Home project so that important new terms can be added, obsolete terms removed, or existing terms updated to significant new insights. This approach has been chosen to reflect the fast-changing decentralised clinical trial landscape. The current version of the glossary can also be found online. ",

author = "Amy Rogers and Rachel Copland and {Houston Pichardo}, Sonia and Kate Harwood and Christa M{\"u}ller-V{\"o}ssing and Petra Naster and Linda Rutgrink and Ute Kohlhaas and {van Veen}, Evert-Ben and Jozef Aerts and Bianca Schnalzer and Christoph Reiter and Robert Rehb",

note = "The research leading to these results has received support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking (H2020-JTI-IMI2) Trials@Home grant n° 831458.",

year = "2020",

month = feb,

day = "28",

language = "English",

publisher = "Trials@Home",

type = "Other",

}

TY - GEN

T1 - D2.1 - Glossary of terms and definitions used

AU - Rogers, Amy

AU - Copland, Rachel

AU - Houston Pichardo, Sonia

A2 - Harwood, Kate

A2 - Müller-Vössing, Christa

A2 - Naster, Petra

A2 - Rutgrink, Linda

A2 - Kohlhaas, Ute

A2 - van Veen, Evert-Ben

A2 - Aerts, Jozef

A2 - Schnalzer, Bianca

A2 - Reiter, Christoph

A2 - Rehb, Robert

N1 - The research leading to these results has received support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking (H2020-JTI-IMI2) Trials@Home grant n° 831458.

PY - 2020/2/28

Y1 - 2020/2/28

N2 - This document reports the processes used to develop a glossary of terms and definitions used within WP2 (task 2.1.1). The consortium agreed to expand the WP2 glossary to a project-level glossary since a common language should be established not only within but also across work packages. The aim of the glossary is to establish a common language within the project and to aid understanding of key terms that will feature in project outputs. The glossary itself, presented in the document, may be updated during the Trials@Home project so that important new terms can be added, obsolete terms removed, or existing terms updated to significant new insights. This approach has been chosen to reflect the fast-changing decentralised clinical trial landscape. The current version of the glossary can also be found online.

AB - This document reports the processes used to develop a glossary of terms and definitions used within WP2 (task 2.1.1). The consortium agreed to expand the WP2 glossary to a project-level glossary since a common language should be established not only within but also across work packages. The aim of the glossary is to establish a common language within the project and to aid understanding of key terms that will feature in project outputs. The glossary itself, presented in the document, may be updated during the Trials@Home project so that important new terms can be added, obsolete terms removed, or existing terms updated to significant new insights. This approach has been chosen to reflect the fast-changing decentralised clinical trial landscape. The current version of the glossary can also be found online.

M3 - Other contribution

PB - Trials@Home

ER -

D2.1 - Glossary of terms and definitions used

Abstract

Access to Document

Fingerprint

Projects

Trials@Home: Center of Excellence – Remote Decentralised Clinical Trials (Joint with 30 other participants, University Medical Centre Utrecht as lead)

Research output

D1.1 First set of recommendations for RDCTs (to be implemented in the pan-EU pilot DCT)

D1.2 Criteria for selection of appropriate trials

Cite this